Our results thus far demonstrate that AML blast survival is directly targeted by MIF inhibition, and this is more efficient when MΦ has been reprogrammed with the MIF inhibitor 4-IPP combined with GM-CSF, reversing the pernicious effects of blasts on MΦ. The gene discussed is MIF; the disease is acute myeloid leukemia.